Public statement on the use of herbal medicinal products containing thujone

Draft

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discussion in Working Party on Community monographs and Community list (MLWP)</td>
<td>November 2010 - January 2011</td>
</tr>
<tr>
<td>Adoption by Committee on Herbal Medicinal Products (HMPC) for release for consultation</td>
<td>27 January 2011</td>
</tr>
<tr>
<td>End of consultation (deadline for comments). Comments should be provided using this template to <a href="mailto:hmpc.secretariat@ema.europa.eu">hmpc.secretariat@ema.europa.eu</a></td>
<td>15 May 2011</td>
</tr>
<tr>
<td>Rediscussion in Working Party on Community monographs and Community list (MLWP)</td>
<td></td>
</tr>
<tr>
<td>Adoption by Committee on Herbal Medicinal Products (HMPC)</td>
<td></td>
</tr>
</tbody>
</table>

Keywords

Herbal medicinal products (HMP); HMPC; well-established medicinal use; traditional use; thujone
Public statement on the use of herbal medicinal products containing thujone

Table of contents

1. Introduction (Problem statement) .......................................................... 3
  1.1. Thujone ............................................................................................................ 3
  1.2. Thujone is a natural constituent of the essentials oils of a number of plants widely used3

2. Discussion ............................................................................................... 3
  2.1. Regulatory status of thujone or thujone-containing products ......................... 4
  2.2. Mechanism of toxic action of thujone ............................................................ 6
  2.3. Single dose toxicity ........................................................................................ 4
  2.4. Repeat dose toxicity ..................................................................................... 4
  2.5. Chronic toxicity ............................................................................................. 5
  2.6. Genotoxicity and carcinogenicity of thujone .................................................... 5
  2.7. Acute (and chronic) toxicity to humans .......................................................... 6
  2.8. Pharmacokinetics of thujone ......................................................................... 6

3. Conclusions and recommendations......................................................... 7

4. References .............................................................................................. 8
1. Introduction (Problem statement)

During the assessments of Artemisia absinthium L. (monograph EMA/HMPC/234463/2008) and Salvia officinalis L. (monograph EMA/HMPC/331653/2008), it became apparent that the risk assessment of thujone, a major component in both herbal preparations, poses considerable uncertainties and difficulties. Thujone has been regarded as a severe neurotoxicant since 1800’s, although recently differing views have been expressed. Difficulties culminated in the determination of maximum limit of daily intakes of thujone, which in the case of Absinthii herba was set at 3.5 mg/person and in the case of sage leaf preparations 5.0 mg/person, both for a maximum duration of 2 weeks. Furthermore, the HMPC has concluded that the benefits of sage essential oil do not outweigh its risks (Public statement EMA/HMPC/41843/2009). Considering that thujone is a natural constituent of the essentials oils of a number of plants widely used, the HMPC decided to prepare a public statement on the use of herbal medicinal products containing thujone.

1.1. Thujone

Thujone occurs in nature as a variable mixture of α-thujone (CAS Number: 546-80-5) and β-thujone (CAS Number: 471-15-8).

Synonyms: Thujon; α-thujone; (-)-thujone; (-)-isothujone; (1S, 4R, 5R)-(-)-3-thujanone; β-thujone; (+)-thujone.

1.2. Thujone is a natural constituent of the essentials oils of a number of plants widely used

<table>
<thead>
<tr>
<th>Essential oil</th>
<th>α-thujone %</th>
<th>β-thujone %</th>
<th>Total (α + β) %</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cedar leaf</td>
<td>55.0</td>
<td>9.5</td>
<td>64.5</td>
<td>Pinto-Scognamiglio, 1967</td>
</tr>
<tr>
<td>Sage</td>
<td>28.3</td>
<td>14.5</td>
<td>42.5</td>
<td>Pinto-Scognamiglio, 1967</td>
</tr>
<tr>
<td></td>
<td>ND*</td>
<td>ND*</td>
<td>55.2</td>
<td>Farag et al., 1986</td>
</tr>
<tr>
<td>Tansy</td>
<td>19.4</td>
<td>58.0</td>
<td>77.4</td>
<td>Pinto-Scognamiglio, 1967</td>
</tr>
<tr>
<td>Wormwood</td>
<td>0.53-1.22</td>
<td>17.5-42.3</td>
<td>ND*</td>
<td>Lawrence, 1995</td>
</tr>
<tr>
<td>Thyme</td>
<td>ND*</td>
<td>ND*</td>
<td>0.2</td>
<td>Farag et al., 1986</td>
</tr>
<tr>
<td>Rosemary</td>
<td>ND*</td>
<td>ND*</td>
<td>4.2</td>
<td>Farag et al., 1986</td>
</tr>
</tbody>
</table>

* not determined

Thujone has also been reported to occur in plants such as Juniperus spp and Cedrus spp., but its content has not been determined.

2. Discussion

This evaluation benefited from extensive literature searches during the preparation of assessment reports of wormwood and sage. Furthermore, the relevant literature on thujone and thujone-containing preparations were searched principally via PubMed until November 2010.
2.1. Regulatory status of thujone or thujone-containing products

The Council of Europe (1999) allocated for thujone a tolerable daily intake (TDI) of 10 µg/kg body weight/day based on a NOEL for convulsions of 5 mg/kg body weight in the female rat, dosed by gavage on 6 days per week for 14 weeks, to which a safety factor of 500 was applied. The Scientific Committee on Food (SCF) confirmed this assessment (SCF 2002). The SCF noted that the consumption of as much as 1 litre of an alcoholic beverage containing 5 mg/l would result in an intake of about 0.08 mg thujone/kg body weight for a 60 kg adult. This intake is about 100 times lower than the NOEL derived from a 14 week study in rats.

According to the Directive 88/388/EEC 1988 a maximum thujone level of 5 mg/kg in alcoholic beverages with not more than 25% volume of alcohol and of 35 mg/kg in alcohol labelled as bitters (40% volume of alcohol and more) are allowed. Taking into consideration a daily intake of 4-8 cl (40-80 ml), this amount corresponds to approximately 0.2-0.4 mg thujone per person (25% volume of alcohol) and 1.2-2.4 mg thujone per person (bitters), respectively. This is without any restriction in duration of use.

Thujone is not authorized for use as a flavouring substance in the USA.

According to the SCF (2002), in France and the United Kingdom the mean daily intake of thujone is estimated to be between 0.27 and 1.09 mg/person (70 kg).

2.2. Mechanism of toxic action of thujone

The mechanism of α-thujone neurotoxicity has been convincingly elucidated in experimental animal studies. α-thujone is a rapidly acting modulator of the GABA-gated chloride channel. The effect appears to be due to the parent compound (Höld et al. 2000; 2001]. α-thujone is more potent than β-thujone (about 2 to 3-fold) or 7-hydroxy-α-thujone (about 56-fold) in the GABA_A receptor binding assay. The effective concentrations of α-thujone in various GABA_A related assays were between 10 and 30 µM. The neuronal effect seems to be completely reversible. The highest measured brain concentrations at 2.5 min of α-thujone and 7-hydroxy-α-thujone after the i.p. administration of α-thujone at the dose of 50 mg/kg were about 11 and 29 ppm, respectively, at the time of severe poisoning signs.

Thujone may be porphyrinogenic (Bonkovsky et al. 1992).

2.3. Single dose toxicity

The most prominent symptoms associated with acute intoxication are epileptiform convulsions, which are in line with the proposed mechanism of action. The oral LD₅₀ of a mixture from α- and β-thujone has been reported with 192 mg/kg in rats, 230 mg/kg in mice and 396 mg/kg in guinea pigs (Margaria 1963). The s.c. LD₅₀ of α-thujone was given with 134 mg/kg in mice and that of β-thujone with 442 mg/kg in mice (Rice and Wilson 1976). In rats, i.p. administrations of thujone led to both convulsant and lethal effects at a dose of 180 mg/kg body weight (Pinto-Scognamiglio 1967, SCF 2002). The i.p. LD₅₀ of α-thujone in mice was 45 mg/kg body weight (Höld et al. 2000). The i.v. LD₅₀ in the rat was 0.031 mg/kg body weight (NTP 2003).

2.4. Repeat dose toxicity

Thujone was administered to rats by gavage at doses of 0, 5, 10 or 20 mg/kg/day 6 times per week for 14 weeks. There were 3 deaths in females and 1 in males associated with convulsions at the top dose level. The NOEL for convulsions was reported to be 10 mg/kg in males and 5 mg/kg in females; no changes were reported in haematologic or histopathologic examinations (Margaria 1963).
In the NTP testing programme, α-thujone and isomeric mixture were administered by gavage to B6C3F1 mice and to Fischer 344 rats at doses of 0, 1, 3, 10, 30 or 100 mg/kg for 14 days. In both species, the increased mortality observed in the top dose group was associated with indications of neurotoxicity (hyperactivity, tremors, tonic seizures) (SCF 2002).

The 13-week NTP study was essentially similar to the 2-week study except the duration. The results can be extracted from the NTP website; the report is due in the future.

2.5. Chronic toxicity

There are no reliable studies of the long-term effects of sub-convulsive doses either on the nervous system or on the liver for the essential oil or thujone. Some results of the long-term toxicity and carcinogenicity studies from the NTP study have been extracted from the NTP website by Lachenmeier and Uebelacker (2010). Isomeric mixture of thujone was administered by gavage to B6C3F1 mice at doses of 0, 3, 6, 12, and 25 mg/kg body weight/day and to Fischer 344 rats at doses of 0, 12.5, 25, and 50 mg/kg body weight/day for 2 years. In both species, the increased mortality observed in the top dose group, and in the rat also in the middle dose group. Clonic and tonic seizures were observed in the middle and top dose groups in rats and in the top dose group in mice. A small increase in clonic seizures was observed also in the low dose group in rats. In the rat, NOEL value was 12.5 mg/kg for mortality and tonic seizures (no NOEL for clonic seizures). In the mouse, the NOEL was 12 mg/kg body weight for seizures and mortality.

Reproductive toxicity studies have not been performed.

2.6. Genotoxicity and carcinogenicity of thujone

In connection with the NTP study (NTP 2010, TR No. 570, accessed 24/01/2011), genotoxic potential of racemic thujone (used in the carcinogenicity study) and α-thujone were investigated according to the NTP protocols. The Ames test results of both compounds were negative in the presence or absence of the activating enzyme system. In vivo, daily exposure by gavage to racemic thujone (6.25, 12.5, 25, 50, or 75 mg α, β-thujone/kg body weight) for 3 months did not result in an increase in micronucleated erythrocytes in the peripheral blood of male B6C3F1 mice. However, female mice had a small but significant increase in micronucleated erythrocytes in the peripheral blood at the end of the 3-month study. Racemic thujone did not induce bone marrow toxicity.

According to the draft NTP report (TR No. 570; draft not yet finalized, but was accessed via NTP website on 24/01/2011) on 2-year gavage studies with rats (dose levels 12.5, 25, and 50 mg/kg) and mice (dose levels 3, 6, 12, 25 mg/kg), there was some evidence of carcinogenic activity of α, β-thujone in male F344/N rats based on increased incidences of preputial gland neoplasms at the dose level of 25 mg/kg (all rats at 50 mg/kg died before the end of the study); increased incidences of benign pheochromocytoma of the adrenal medulla may have been related to administration of α, β-thujone in male F344/N rats administered 12.5 or 25 mg/kg. There was no evidence of carcinogenic activity of α, β-thujone in female F344/N rats administered 12.5 or 25 mg/kg. There was no evidence of carcinogenic activity of α, β-thujone in male or female B6C3F1 mice administered 3, 6, or 12 mg/kg.

In the same 2-year study, administration of α, β-thujone resulted in increased incidences of seizures in F344/N rats and B6C3F1 mice in a dose-dependent manner and increased incidences of nonneoplastic lesions in the brain and spleen of male and female F344/N rats, the kidney of male F344/N rats and the pituitary gland of female F344/N rats usually at the two highest dose levels (25 and 50 mg/kg).
2.7. Acute (and chronic) toxicity to humans

Cases with severe intoxications in humans have been reported after consumption of essential oil rich in thujone (Centini et al. 1987, Milette et al. 1981). Convulsions resembling epilepsy have been reported after the ingestion of isolated thujone (Cobb 1922). Overdosage of alcoholic Absinthii herba preparations or the use of the essential oil may cause CNS disturbances which can lead to convulsions and ultimately to unconsciousness and death (Gessner 1974, Roth et al. 1994). Although it is difficult to determine exposing doses in these cases, SCF (2002) concluded that humans are at least as sensitive to thujone neurotoxicity as experimental animals.

In a clinical study by Dettling et al. (2004), 25 volunteers were exposed to absinthe containing high (100 mg/l) and low (10 mg/l) concentrations of thujone. Approximate thujone amounts consumed were 0, 1.5 mg and 15 mg. The simultaneous administration of alcohol containing a high concentration of thujone had a negative effect on attention performance and some mood dimensions at the earliest examination time (30 min). Alcohol alone or with a low concentration of thujone did not result in similar effects. The authors interpreted the observations at a high thujone dose as the antagonistic effect of thujone on the GABA_A receptor.

In a pilot absinthe drinking study by Kröner et al. (2005), two subjects consumed 110 ml absinthe with 3.85 mg thujone (content of absinthe 35 mg/l) within 15 min, 15 and 30 min and then every 30 min until up to 2 h after drinking blood samples were drawn. Blood alcohol concentrations >1 g/l were observed whereas no thujone could be detected in blood samples (detection limit 0.34 ng/ml). Conjugates of thujone were not determined. The two subjects showed typical signs of alcohol effects (e.g. staggering, chattiness) while hallucinogenic effects were not described.

2.8. Pharmacokinetics of thujone

Metabolism of thujone has been investigated in mouse, rat and human liver preparations in vitro and in mice, rats and (partially) rabbits in vivo. Hydroxylations at various positions, followed to a different extent by glucuronidation, and reductions as minor reactions are principal metabolic pathways, although in vitro and in vivo metabolic profiles do not necessarily agree with each other (Ishida et al. 1989, Höld et al. 2000; 2001).

In in vitro liver microsomal incubations with α-thujone, 7-hydroxy-α-thujone seems to be a major metabolite in mice, rats and humans, whereas with β-thujone, formation of 4-hydroxy-β-thujone exceeded that of 7-hydroxymetabolite in all species. 2-hydroxy-thujone was observed only in mouse liver microsomes. Earlier studies indicated that among human recombinant P450 enzymes studied, CYP3A4 and CYP2D6 were the most active enzymes, producing 7-hydroxy-α-thujone, 4-hydroxy-thujone (in this order of abundance) and some minor metabolites. CYP1A2, CYP2C9, CYP2C19, and CYP2E1 were less active, catalyzing only about 1% conversion in one hour of incubation (Höld et al. 2001, Jiang et al. 2006). The latest study (Abass et al. 2010) with a more comprehensive set of recombinant enzymes indicate that the principal CYP enzyme metabolizing α-thujone is CYP2A6, followed by CYP3A4 and, to a small extent, CYP2B6. The major metabolites produced were 7- and 4-hydroxyl compounds. Extrapolation of microsomal metabolic clearances suggested that α-thujone is a liver blood flow–dependent substance.

Incubation of α-thujone with rabbit (but not mouse) liver cytosol led to the reduction products, thujol and neothujol, in low yield (Höld et al. 2000; 2001). 7,8- and 4,10-dehydro metabolites have been identified in vitro and as urinary metabolites respectively (Höld et al. 2001).

In mice treated with α-thujone in vivo, surprisingly 2-hydroxy-α-thujone (mostly as a glucuronide) was the principal metabolite in urine, whereas 7-hydroxy-β-thujone was by far the most abundant urinary
metabolite after β-thujone administration. In the rat, 4-hydroxy-thujones were principal urinary metabolites after thujone administrations (Höld et al. 2001).

3. Conclusions and recommendations

Human intoxications by thujone-containing preparations have indicated that animal studies are of relevance to the human situation. However, dose-effect comparisons are uncertain. It seems that low doses (of the order of 1.5 to 3.85 mg) have no or very little effects whereas higher doses (15 mg) clearly affected CNS measures.

There are no preclinical or clinical studies which would permit reliable scientific assessment of potential consequences regarding exposure of sensitive groups (i.e. pregnant women, children etc). Thus the use of thujone-containing herbal medicinal products in these groups should be minimised.

According to the current view, it is not possible to infer any useful material or conclusions for thujone toxicity from the phenomenon of absinthism (e.g. Lachenmeier et al. 2006).

Studies on human liver preparations and enzymes in vitro indicate that CYP2A6, and CYP3A4 and CYP2B6 to a lesser extent, are principal thujone-metabolizing enzymes at least in vitro (Höld et al. 2001, Jiang et al. 2006, Abass et al. 2010). Clearance calculations point to a possibility of a prominent first-pass metabolism. Induction and inhibition interactions with drugs after oral administration in humans are probably not likely because of multiple metabolizing enzymes and a fairly rapid metabolism. However, metabolic and pharmacokinetic characteristics remain inadequately defined and need further studies.

Because maximum daily intake (acceptable daily intake (ADI) for food) is a measure of the amount of a specific substance that can be ingested (orally) over a lifetime without an appreciable health risk, for a limited intake, such as herbal medicinal preparations, the limit values of thujone can be set higher than the dietary intake. On this basis, the HMPC has recommended that, at the present moment, the rat 14-week study would be taken as a basis of assessment, with an uncertainty factor of 100. This would mean a daily intake of 3.5 mg of thujone/person (70 kg). The content of thujone must be shown for every batch.

However, it has to be kept in mind that the average dietary daily intake might already be between 0.3 and 1 mg thujone/person, which would lead together with the intake of an HMP to a daily intake of 3.8-4.5 mg thujone/person. That would mean in comparison to the 14-weeks study in rats safety factors of 77-92. The intake by food cannot be ignored, because patients have no influence on it. The daily intake by food should be in general lower than the postulated TDI of 0.7 mg/person and by using the HMP, the daily dose to thujone is increased by at least 3 times. The basic thujone-impact by food needs some further consideration.

Recently, Lachenmeier and Uebelacker (2010) have performed a detailed re-evaluation of the available evidence using the benchmark dose (BMD) approach and found that the application of the appropriate dose-response modelling on the long-term chronic toxicity study of the NTP, using clonic seizures as a response, yielded a BMD lower confidence limit for a benchmark response of 10% (BMDL10) as 11 mg/kg body weight/day. Applying the uncertainty factor of 100, an ADI of 0.11 mg/kg was calculated, yielding a limit dose of 6.6 mg/day for a standard human being.

According to the study of Dettling et al. (2004) as a basis, a single dose of 0.28 mg/kg in men (20 mg/70 kg) and of 0.24 mg/kg (17 mg/70 kg) gives a significant pharmacological effect, although the effect as such is of “borderline relevance”, i.e. mainly related to driving, operating machinery etc. A safety margin that covers the small number of subjects, repeated use, possible effects of other herbal constituents on metabolism etc is needed.

Public statement on the use of herbal medicinal products containing thujone
EMA/HMPC/732886/2010
The "therapeutic margin" of thujone where effects may start at those borderline effects and end in seizures is not known and its determination would need further studies. However, on the basis of the above mentioned limit doses of 3.5 and 6.6 mg/day, it is recommended that the amount of thujone in a preparation needs to be specified and that exposures in the range between 3 and 7 mg/day do not pose special concerns (a range may allow a simpler analytical method for setting the specification). For higher concentrations a case-by-case benefit/risk assessment would be necessary. The amount of dietary intake of 1 mg in average may not cause special concerns. However, for the upper limit of the additional intake from medicinal products, the highest safe amount was reduced by the possible intake by food, to give 6 mg as a limit of daily exposure.

Upon finalisation of this public statement, a revision of the monographs on wormwood and sage is envisaged.

4. References


